Last reviewed · How we verify
NCT07387224: NECPAL_HUIL
Identification of Patients With Advanced Chronic Diseases in Need of Palliative Care
trial in Advanced Chronic Disease in 200 participants. Participants enrolled and being followed up; not accepting new ones.
1 February 2028
Quick facts
| Lead sponsor | Infanta Leonor University Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 February 2024 |
| Primary completion | 1 February 2028 |
| Estimated completion | 1 February 2028 |
| Sites | 2 locations across Spain |
Conditions studied
- Advanced Chronic Disease — all drugs for Advanced Chronic Disease →
- Palliative Care — all drugs for Palliative Care →
- Chronic Disease — all drugs for Chronic Disease →
- Multimorbidity — all drugs for Multimorbidity →
Sponsor
Infanta Leonor University Hospital
Who can join
18 and older, any sex, with Advanced Chronic Disease or Palliative Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with advanced chronic diseases often have complex health needs and may benefit from palliative care. However, many of these patients are not identified early enough to receive appropriate palliative care interventions. This prospective observational study aims to identify hospitalized patients and patients attending a day hospital with advanced chronic conditions who have palliative care needs, using the NECPAL tool. NECPAL is a validated screening instrument designed to identify patients with advanced chronic diseases who may benefit from palliative care, based on clinical indicators, disease progression, functional decline, and health care utilization. Adult patients with advanced oncological and non-oncological chronic diseases will be consecutively evaluated. The NECPAL tool will be applied by trained investigators as part of routine clinical assessment. Patients will be classified as NECPAL positive or NECPAL negative according to predefined criteria. The study will estimate the proportion of patients identified as NECPAL positive, describe their clinical characteristics, and analyze whether they are receiving palliative care. Secondary objectives include comparing clinical variables, comorbidity indices, and mortality between NECPAL-positive and NECPAL-negative patients over follow-up. The results of this study will provide information on the prevalence of palliative care needs among patients with advanced chronic diseases and support early identification strategies in hospital settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07387224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Infanta Leonor University Hospital trials
Trials by the same sponsor.
- NCT07372170 — Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic AP · recruiting
- NCT07310693 — External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07387224 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Infanta Leonor University Hospital
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07387224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing